

German Delegation

STARTUP

at PANATHĒNEA 2026

27. – 29.05.2026

Athens



Dr. Alejandro Rojas-Fernandez
CEO
Alejandro.rojas@berkinglife.de



Berking Theranostics is a Hamburg-based biotech startup developing **RadioNabs®**—precision cancer theranostics that combine **alpaca-derived nanoantibodies** with **radioligand therapy** to both diagnose and treat solid tumors with high specificity and fewer side effects than conventional therapies. The company aims to advance targeted radiopharmaceuticals for cancers like breast and prostate and is currently in a **seed funding round** to accelerate development.

Year founded 2023
Locations: Hamburg

What We Build:

We are advancing personalized diagnostic and therapeutic solutions to improve the treatment of solid tumors.

The Problem We Solve:

We are developing highly specific immunotherapies to treat currently incurable tumors and to overcome the side effects of chemotherapy

Why We Stand Out (Our USP)

Our proprietary method enables the generation of **RadioNabs**, a unique type of single-domain antibody derived from the alpaca immune system link to radioactive particle.

Where We Are in Our Funding Journey:

- Bootstrapped
- Pre-Seed
- Seed
- Series A

Where We Are on Our Product Journey:

- Idea
- MVP
- Market readiness
- Scaling

Our Target Customers & Industry:
Nuclear medicine centers and Hospitals

Who We're Looking to Meet:

We are seeking investors who believe in our technology, as well as those with experience in the biotechnology sector, who can help accelerate our development and bring our solutions to global markets.



Winkler, Sebastian, PhD
CEO
Seb.Winkler@Momentum-Transfer.com



Momentum Transfer revolutionizes materials characterization by providing synchrotron-quality X-ray measurements as a cloud service. We deliver 1000x measurement capacity, 100x better data quality, and 10x lower cost compared to traditional lab equipment—without CAPEX. Accelerating sustainable materials innovation for batteries, pharmaceuticals, catalysts, mining, and climate- institutions.

Customers ship samples to us. We measure them at contracted beamlines at ESRF (Grenoble) and DESY (Hamburg) using fourth-generation synchrotron facilities with 10,000 samples/day capacity. Our proprietary software handles sample tracking, automated data collection, background subtraction, normalization, and quality assurance. Customers receive analysis-ready data within days—enabling breakthrough innovations in sustainable materials, energy storage, pharmaceuticals, and climate technologies.

Year founded: 2025

Locations: Mannheim, Germany (HQ) | Hamburg, Germany (Sample Preparation Lab) | Grenoble, France (ESRF Operations)

What We Build:

We build the AWS of materials characterization—a cloud-based platform that democratizes access to ultra-high-throughput synchrotron X-ray measurements. Our mail-in service provides industrial materials researchers with world-class characterization capabilities previously accessible only to elite research institutions. This matters because the €15 trillion materials industry (15% of global GDP) is bottlenecked by slow, expensive, inaccessible characterization. To save the world, we need better materials faster. To train materials AI, data is essential for training. To determine progress on new materials - materials characterization is essential. Traditional lab equipment costs €500k-€2M in CAPEX, requires specialized staff, and delivers slowly inferior data. We eliminate these barriers entirely, cutting time-to-market by up to 50% and costs —accelerating the materials innovation critical for decarbonization and sustainable manufacturing.

Why We Stand Out

Exclusive Infrastructure Access: 10-year frame contracts with ESRF (Grenoble) and DESY (Hamburg) provide guaranteed beamtime. Unmatched Performance: 1000x measurement capacity, 100x better data quality, 10x lower cost—all without CAPEX or OPEX. 5-Year Technical Head Start: Proprietary hardware, deeply integrated software, reference database, and operational expertise competitors cannot replicate quickly. Academic-to-Industry Flywheel: Professors using our platform train future industry scientists, publish papers referencing our service, and provide warm industry introductions. Deep Facility Integration: automatic sample registration, real-time data matching, proprietary data treatment. We're not competing on features. We're providing infrastructure access that's fundamentally unavailable elsewhere.

Who We're Looking to Meet:

- Deep-Tech Investors with Materials/Climate Focus:
 - Investors with portfolio companies in advanced materials, sustainability, or industrial innovation
 - VCs who understand "picks and shovels" infrastructure plays
 - Climate-tech focused funds recognizing materials innovation as critical for decarbonization
- Strategic Industry Partners:
 - Pharmaceutical: Companies interested in advanced characterization for drug development
 - Battery & Automotive: Strategic investors/corporates in EV supply chain seeking materials innovation acceleration
 - Mining Companies: Major mining operators or exploration firms needing rapid ore characterization
- Distribution Channel Partners:
 - Contract research organizations (CROs) seeking to white-label our service
 - Measurement service providers expanding their capabilities
- Domain Experts & Advisors:
 - Materials science industry veterans with networks in target sectors

The Problem We Solve:

Materials R&D teams cannot access the characterization quality they need to accelerate innovation. Traditional lab-based X-ray equipment is prohibitively expensive (€500k-€2M CAPEX), requires specialized operators, dedicated lab space, and delivers low-quality data with slow turnaround times. The technology in most corporate and university labs hasn't significantly evolved in 20 years—leaving researchers working with fundamentally limited tools. Industries developing sustainable materials for CO2 reduction (steel, cement), energy storage (batteries), pharmaceuticals, catalysts, and mining face critical bottlenecks. They need to "know for sure" what materials they're creating, but cannot justify synchrotron facility investments or navigate months-long wait times for beamtime access. The problem remains unsolved because accessing world-class synchrotron facilities requires irreplaceable personal relationships with facility directors, expert knowledge of experimental setup and data treatment, and navigating complex booking systems. Most organizations lack all three.

Where We Are in Our Funding Journey:

Pre-Seed

Where We Are on Our Product Journey:

- Market readiness
- Scaling

Our Target Customers & Industry:

We target industrial materials R&D teams and academic research groups across multiple high-value sectors:

Primary Industries:

- Pharmaceuticals (17% of current industry revenue)
- Battery & Energy Storage (PowerCo, automotive suppliers)
- Catalysis (BASF 6 business units, Clariant)
- Mining (targeting gold, rare metals): Ore characterization, mineral identification, processing optimization
- Cement & Construction Materials: CO2 reduction materials, sustainable formulations
- Special Chemicals & CROs (18% of revenue, 88% repeat rate)

Customer Profile:

- R&D directors and senior materials scientists in mid-to-large enterprises
- University professors and research group leaders (academic flywheel)
- Quality control managers in manufacturing (future expansion into ongoing processes)

Geographic Focus: Europe (current), North America (2026 expansion), China (pilot launching 2026), Africa (mining sector via Mining Indaba 2026).

Market Size: €43B+ opportunity (€500M academia, €7.5B high-value projects, €35B+ ongoing manufacturing) within the €15 trillion materials industry.

www.momentum-transfer.com



Anthony Hessel PhD
Co-founder & CEO
Anthony.hessel@ambitech.de



Accelerated Muscle Biotechnologies (AMB) GmbH is a contract research organization for the development and study of skeletal and cardiac muscle in Europe. We conduct deep-tech and technically challenging experiments for academics, healthcare, and drug discovery clients, as well as conduct our own innovation research through government grants. Our sister company, AMB LLC, based in the USA, provides us with easy access to an expanded market of clients and government programs.

Year founded 2025
Locations: Hamburg, Germany / Boston, USA

What We Build:

Accelerated Muscle Biotechnologies (AMB) GmbH is a contract research organization for the development and study of skeletal and cardiac muscle in Europe. We conduct deep-tech and technically challenging experiments for academics, healthcare, and drug discovery clients, as well as conduct our own innovation research through government grants and in-house drug discovery pipelines. Our sister company, AMB LLC, based in the USA, provides us with easy access to an expanded market of clients and government programs.

Where We Are on Our Product Journey:

- Idea
- MVP
- Market readiness
- Scaling

Where We Are in Our Funding Journey:

- Bootstrapped
- Pre-Seed
- Seed
- Series A

The Problem We Solve:

Some of the most useful experiments used within skeletal and cardiac drug development are so complex and unstandardized that few use them well, slowing down scientific knowledge and medical breakthroughs. We design hardware, software, and process solutions for these most complex experiments. These can be implemented to the clients themselves, or more typically, we are contracted to conduct the research ourselves with our expert team of muscle scientists. Our flagship service is X-ray diffraction of muscle cells, which is conducted at special particle accelerators around the world using X-ray 100 billion times stronger than the dentist.

Who We're Looking to Meet:

Skeletal muscle and drug discovery companies looking to perform pre-clinical experiments on their candidate molecules or therapies, either as under subcontractor or partnership agreements. Clients in any area of skeletal and cardiac muscle research should reach out to us. We have in-house drug discovery projects that will interest investors within that space.

Our Target Customers & Industry:

AMB markets include the academic research, drug discovery, and healthcare markets for skeletal and cardiac muscle. Academic market and client base is most developed. Drug discovery is now under business development, and healthcare market (e.g. personalized medicine solutions) is in our future vision.



Sarah Wurzer
Ecosystem Partnerships
Sarah.wurzer@bryck.com



BRYCK STARTUP ALLIANCE

The BRYCK Startup Alliance is one of Germany's 10 Startup Factories. We unite research, industry & growth with one vision: Building Germany's B2B tech powerhouse by accelerating science-based startups and technology transfer from research to industry.

Year founded 2025
Locations: Essen

What We Build:

We build a leading European hub for science-based entrepreneurship. Through the BRYCK Startup Alliance, we accelerate deep-tech spin-offs and fast-track technology transfer from research to industry — turning cutting-edge science into scalable B2B ventures.

Why We Stand Out

We combine scientific excellence, industrial access, and early-stage capital under one coordinated platform. We unite:

- **University Alliance Ruhr** (110,000 students, 14,000 researchers)
- **150,000 sqm of lab & prototyping space**
- **€10M Pre-Seed Fund** (GF BRYCK Ventures)
- Structured access to **€10B+ venture capital**
- **70+ corporates & institutions** via Initiativkreis Ruhr
- Backing by the **RAG Foundation**, one of Germany's largest private foundations

The Problem We Solve:

Germany excels in research, yet struggles to translate scientific excellence into scalable startups. Fragmented ecosystems, limited entrepreneurial pathways, and slow industry transfer hinder innovation. As one of Germany's ten federally recognized Startup Factories, we bridge this gap by systematically connecting universities, capital, and corporates to accelerate science-based ventures.

Who We're Looking to Meet:

- Science-based startups & spin-offs
- Corporate innovation leaders
- Early-stage and deep-tech investors
- Accelerators & ecosystem partners
- Universities and research institutions

Our Target Customers & Industry:

Energy, Chemistry, Prop Tech, Water
Personalized Medicine, New Materials, Secure & Intelligent Systems

We seek long-term partners committed to building Europe's next generation of deep-tech champions.



Iosif Koutsoumpidis
Co founder & CEO
Koutsoumbidis_iosif@yahoo.com



APIRA is a German climate-tech startup developing a patented, pre-installed wildfire protection system for homes and buildings. Operating without water, electricity, or human presence, APIRA offers two solutions—custom removable fire-resistant panels and permanently installed roller systems—protecting buildings autonomously in regions where over 10 million homes are exposed to wildfire risk for more than 6–7 months every year.

Year founded: 2021
Locations: Cologne, Germany

What We Build:

APIRA develops an all-in-one, pre-installed wildfire protection system designed to safeguard homes and buildings at the exact moment a wildfire reaches the structure. Our solution combines advanced fire-resistant materials with a patented installation and deployment methodology and is offered in two complementary formats:

- **Customised removable panels**, precisely fitted to doors and windows, which can be installed or removed within minutes to block flame, ember, and radiant heat entry points.
- **Permanently installed roller systems**, discreetly integrated into the building façade, which can be deployed remotely or automatically, even when no one is present.

Both solutions operate without water, electricity, chemicals, or firefighting intervention, transforming wildfire protection into a permanent structural resilience layer for long-duration wildfire seasons lasting the majority of the year.

Why We Stand Out

APIRA uniquely combines advanced material science with a patented deployment concept to deliver autonomous wildfire protection.

Our system:

- Works **without water, electricity, foam, or chemicals**
- Requires **no human presence** during activation
- Protects for **hours or days**, far exceeding typical wildfire exposure
- Offers two **flexible solutions** (removable panels & permanent rollers)
- Applies to **existing and new buildings**
- **Is reusable, environmentally friendly, and cost-effective**
- Validated through **certified laboratory and university fire tests**, demonstrating resistance to up to 900°C for over 30 minutes and over 70 minutes in extended tests—far exceeding typical wildfire exposure of 2–3 minutes at ~600°C.

Unlike reactive or infrastructure-dependent solutions, APIRA provides proactive, always-ready structural resilience for climate-exposed regions where **wildfire risk persists for most of the year**.

Where We Are in Our Funding Journey:

- Bootstrapped
- Pre-Seed
- Seed
- Series A

Who We're Looking to Meet:

- Climate-tech and impact investors
- Insurance and reinsurance partners
- Real estate developers and construction companies
- Industrial manufacturing partners (aluminum systems & large-scale manufacturing)
- Construction and real estate developers operating in wildfire-prone regions
- Public sector and civil protection stakeholders

The Problem We Solve:

As climate change accelerates, wildfires are becoming more frequent, intense, and unpredictable across Southern Europe and other Mediterranean-climate regions, as well as in the United States and Australia. Once evacuation orders are issued, homeowners are left with no reliable way to protect their properties. Existing solutions rely on last-minute actions, water-dependent sprinkler or chemical foam systems, insurance contracts without physical protection, or manual firefighting efforts that require people to remain on site—often under dangerous conditions. These **methods depend on infrastructure and human intervention that frequently fail during wildfire events**. As a result, entire regions are becoming partially uninsurable, with escalating economic and social losses. APIRA addresses this critical gap by offering autonomous, pre-installed structural protection that works even when infrastructure fails and human presence is impossible and ... **works for days even for weeks!!**.

Where We Are on Our Product Journey:

- Idea
- MVP
- Market readiness
- Scaling

Our Target Customers & Industry:

B2B stakeholders:

- Insurance and reinsurance companies reducing underwriting risk.
- Real estate developers integrating wildfire resilience into new constructions.
- Municipalities and public authorities strengthening climate adaptation strategies.

APIRA operates at the intersection of **climate-tech, construction technology, risk mitigation, and insurtech**. Our primary focus is **B2C**, targeting homeowners with properties in wildfire-prone regions who seek permanent, autonomous protection for their most valuable assets.

We initially focus on **Greece as our pilot market**, where **approximately 4.9 million houses—around 75% of all residential buildings—and 7.9 million people are exposed to wildfire risk**. We then expand to other Mediterranean countries with similar climate and building characteristics - **Italy, Spain, Portugal, France, and Cyprus** - as well as the USA and Australia, representing **over 10 million at-risk homes** globally.

Contact:

Zoi Baltzi
Business Developer

German Hellenic Chamber of Industry
and Commerce

T: +30 210 6419015
z.baltzi@ahk.com.gr



Meet up!

28 & 29.05. at PANATHĒNEA
main venue
Zappeion Megaron

28.05. Scale Abroad: Navigating Germany & the EU
Masterclass into Germany's innovation scene.
at Goethe Institute Athens
15:30 – 18:00

Let's talk opportunities. 1:1 Meetings